Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
暂无分享,去创建一个
S. Lundgren | P. Boffetta | T. Nilsen | J. Creaney | K. Kjaerheim | E. Larsson | O. Røe | H. Sandeck | B. Robinson
[1] Claudio Bianchi,et al. Malignant mesothelioma: global incidence and relationship with asbestos. , 2007, Industrial health.
[2] A. Andersen,et al. Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples , 2007, International journal of cancer.
[3] M. Copin,et al. Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment , 2007, Clinical Cancer Research.
[4] N. Sardesai,et al. MESOMARK: a potential test for malignant pleural mesothelioma. , 2007, Clinical chemistry.
[5] Y. Takeshima,et al. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma , 2007, Pathology international.
[6] Mitchell Ho,et al. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. , 2007, Bioconjugate chemistry.
[7] B. Garvik,et al. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. , 2007, Cancer letters.
[8] Mitchell Ho,et al. Mesothelin Expression in Human Lung Cancer , 2007, Clinical Cancer Research.
[9] Mitchell Ho,et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.
[10] Mitchell Ho,et al. Mesothelin Is Shed from Tumor Cells , 2006, Cancer Epidemiology Biomarkers & Prevention.
[11] S. Pandita. Banning Asbestos in Asia: Campaigns and Strategies by the Asian Network for the Rights of Occupational Accident Victims (ANROAV) , 2006, International journal of occupational and environmental health.
[12] M. Copin,et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. , 2006, American journal of respiratory and critical care medicine.
[13] N. Sardesai,et al. Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic Marker , 2006, Cancer Epidemiology Biomarkers & Prevention.
[14] A. Gown,et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity , 2006, Modern Pathology.
[15] S. Rubin,et al. Screening for ovarian cancer in the general population. , 2006, Best practice & research. Clinical obstetrics & gynaecology.
[16] A. Olshen,et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.
[17] I. Shih,et al. Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma , 2006, Clinical Cancer Research.
[18] Alan T. Remaley,et al. Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer , 2006, Clinical Cancer Research.
[19] J. Creaney,et al. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. , 2005, Hematology/oncology clinics of North America.
[20] S. Touloupidis,et al. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. , 2005, The Journal of urology.
[21] Wei Zhang,et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer , 2005, BMC Cancer.
[22] R. Gaafar,et al. Epidemic of mesothelioma in Egypt. , 2005, Lung cancer.
[23] R. Jensen,et al. Validation of Genomics-Based Prognostic Tests in Malignant Pleural Mesothelioma , 2005, Clinical Cancer Research.
[24] K. Ohtsubo,et al. Expression of Mesothelin mRNA in Pure Pancreatic Juice From Patients With Pancreatic Carcinoma, Intraductal Papillary Mucinous Neoplasm of the Pancreas, and Chronic Pancreatitis , 2005, Pancreas.
[25] H. Grassos,et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters , 2005, European journal of heart failure.
[26] J. Mate,et al. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients , 2005, Leukemia & lymphoma.
[27] E. Hovig,et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study , 2004, British Journal of Cancer.
[28] N Urban,et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.
[29] I. Pastan,et al. Mesothelin , 2004, Clinical Cancer Research.
[30] N. Umesaki,et al. Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.
[31] K. Müller,et al. Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register , 2004, International archives of occupational and environmental health.
[32] E. Bleecker,et al. Changing patterns in asbestos-induced lung disease. , 2004, Chest.
[33] A. Musk,et al. Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.
[34] N. Ordóñez,et al. Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.
[35] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Ken Takahashi,et al. A Cross-country Comparative Overview of the Asbestos Situation in Ten Asian Countries , 2003, International journal of occupational and environmental health.
[37] A. Hjerpe,et al. Growth factors regulate the expression profile of their syndecan co-receptors and the differentiation of mesothelioma cells. , 2003, Anticancer research.
[38] B. Adapinar,et al. CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature , 2003, European Radiology.
[39] P. Baas. Predictive and prognostic factors in malignant pleural mesothelioma , 2003, Current opinion in oncology.
[40] A. Gazdar,et al. SV40 and human tumours: myth, association or causality? , 2002, Nature Reviews Cancer.
[41] I. Uçgun,et al. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. , 2002, Chest.
[42] K. O'Byrne,et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] J. Leigh,et al. Malignant mesothelioma in Australia, 1945-2000. , 2002, American journal of industrial medicine.
[44] N. Siafakas,et al. Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer , 2002, Respiration.
[45] P. Clement,et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women , 2002, Cancer.
[46] I. Uçgun,et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. , 2001, Respiratory medicine.
[47] S. Parodi,et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. , 2001, Chest.
[48] J. Testa,et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey , 2001, The Lancet.
[49] E. Glattre,et al. Effect of long-term storage on the concentration of albumin and free fatty acids in human sera , 2001, Scandinavian journal of clinical and laboratory investigation.
[50] A. Hjerpe,et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. , 2000, American journal of clinical pathology.
[51] A. van Dalen,et al. A profile of tumor markers in the population of Kuwait. , 1999, Anticancer research.
[52] B. Weyn,et al. Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.
[53] J. Herndon,et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.
[54] H. Bruckner,et al. Tumor markers in patients with pancreatic carcinoma , 1996, Cancer.
[55] S. Constantopoulos,et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? , 1996, The European respiratory journal.
[56] I. Pastan,et al. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. Andersen,et al. Experiences of the Janus Serum Bank in Norway. , 1995, Environmental health perspectives.
[58] C. Muirhead,et al. Residential radon exposure and lung cancer—an epidemiological study of Norwegian municipalities , 1994, International journal of cancer.
[59] A. van Dalen,et al. Reference levels of the tumor markers carcinoembryonic antigen, the carbohydrate antigens 19-9 and 72-4, and cytokeratin fragment 19 using the Elecsys Relecsys 1010 analyzer in a normal population in Kuwait. The importance of the determination of local reference levels. , 2002, The International journal of biological markers.